Search - tctmd.com

Displaying 381 - 400 of 1231

Sort: Relevancy | Date

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

ESC Updates Guidance on Management of Acute Pulmonary Embolism

News Conference News ESC 2019

ESC Updates Guidance on Management of Acute Pulmonary Embolism

September 06, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

News Conference News ESC 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

August 31, 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

August 31, 2019

Use of IVC Filters for DVT Peaked in 2010 but Remains High

News Daily News

Use of IVC Filters for DVT Peaked in 2010 but Remains High

Michael O'Riordan

August 28, 2019

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

News Daily News

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

August 27, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

TAVR Bleeds Stand Apart From PCI-Related Events

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

August 06, 2019

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

News Daily News

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

August 05, 2019

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

News Daily News

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

July 23, 2019

Liberal IVC Filter Use Not Warranted in Severe Trauma Patients

News Daily News

Liberal IVC Filter Use Not Warranted in Severe Trauma Patients

July 08, 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

TCTMD’s Top 10 Most Popular Stories for June 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

June 28, 2019

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

News Features

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

June 25, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.